GLP-1 and CRP: Inflammation Tracking

Chronic low-grade inflammation is one of the most damaging consequences of obesity, contributing to heart disease, diabetes, cancer, and accelerated aging. CRP (C-reactive protein) is the primary blood marker for systemic inflammation, and GLP-1 medications consistently reduce it. Tracking CRP during GLP-1 treatment reveals health improvements that go far beyond what the scale shows.

What CRP Measures

CRP is a protein produced by the liver in response to inflammation. The high-sensitivity CRP (hs-CRP) test detects low levels of chronic inflammation:

• Low risk: Below 1.0 mg/L
• Average risk: 1.0-3.0 mg/L
• High risk: Above 3.0 mg/L
• Very high: Above 10 mg/L (may indicate acute infection rather than chronic inflammation)

Obese individuals frequently have hs-CRP levels above 3.0 mg/L, sometimes significantly higher. This chronic inflammation drives arterial damage, insulin resistance, and cellular aging. Reducing CRP is one of the most important health improvements you can achieve.

How GLP-1 Reduces Inflammation

• Fat tissue reduction: Adipose tissue is a major source of inflammatory cytokines. Losing fat directly reduces inflammatory molecule production
• Direct anti-inflammatory effects: GLP-1 receptors are found on immune cells, and GLP-1 activation appears to reduce inflammatory signaling
• Improved insulin sensitivity: Insulin resistance itself promotes inflammation; improving it breaks the cycle
• Gut health: GLP-1 may improve gut barrier function, reducing inflammation from bacterial translocation

Expected CRP Improvements

Clinical studies show significant CRP reductions with GLP-1 treatment:

• Average hs-CRP reduction of 20-40% over 6-12 months
• Patients with the highest baseline CRP often see the most dramatic improvements
• CRP improvements often precede the full weight loss, suggesting direct anti-inflammatory medication effects
• Many patients move from "high risk" to "average risk" or "low risk" categories

Why CRP Reduction Matters

Reducing CRP has concrete health implications:

• Cardiovascular risk: Each mg/L reduction in CRP is associated with meaningful reduction in heart attack and stroke risk
• Cancer risk: Chronic inflammation promotes cancer development; reducing it may lower risk
• Joint health: Lower systemic inflammation reduces joint pain and progression of osteoarthritis
• Brain health: Neuroinflammation is linked to cognitive decline; reducing systemic inflammation may have neuroprotective effects
• Aging: "Inflammaging" is a recognized driver of accelerated biological aging

Monitoring Schedule

• Baseline: hs-CRP before starting GLP-1 treatment
• 6 months: Check for improvement
• 12 months: Comprehensive assessment
• Annually: Ongoing cardiovascular risk monitoring

Note: CRP can spike temporarily from acute illness, injury, or infection. If your CRP is unexpectedly high, your provider may recheck after recovery to get an accurate baseline.

Getting Started

CRP monitoring can be part of your GLP-1 treatment plan at Trimi. Visit our treatment options page. Compounded semaglutide is $99/month and tirzepatide is $125/month.

Frequently Asked Questions

Does GLP-1 reduce inflammation?

Yes. GLP-1 medications reduce CRP (a marker of systemic inflammation) by 20-40% on average through both direct anti-inflammatory effects and the benefits of weight loss and improved metabolic health.

How quickly does CRP improve on GLP-1?

Some improvement may be detectable within 3 months. Most significant CRP reduction occurs over 6-12 months as weight loss accumulates alongside the medication's direct anti-inflammatory effects.

Should I ask my doctor to check CRP?

Yes. hs-CRP is an inexpensive test that provides valuable information about your inflammatory status and cardiovascular risk. It is a useful marker to track before and during GLP-1 treatment.

Can CRP reduction reduce my heart disease risk?

Yes. CRP is an independent predictor of cardiovascular events. Reducing CRP through GLP-1 treatment, weight loss, and improved metabolic health directly contributes to lower heart disease and stroke risk.